Brilinta’s patent nullification competition fueled even more among pharmaceutical companies
While domestic pharmaceutical companies are competing over the patent nullification of the AstraZeneca’s antithrombotic, ‘Brilinta,’ the recent establishment of many claims for the patent is expected to solidify the competition.
Recently, the Intellectual Property Tribunal ruled establishment of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
